210 related articles for article (PubMed ID: 16460134)
1. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.
Salkever D; Slade E; Karakus M
Pharmacoeconomics; 2006; 24(2):123-39. PubMed ID: 16460134
[TBL] [Abstract][Full Text] [Related]
2. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.
Stargardt T; Edel MA; Ebert A; Busse R; Juckel G; Gericke CA
J Clin Psychopharmacol; 2012 Oct; 32(5):602-7. PubMed ID: 22926592
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of atypicals in the UK.
Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
[TBL] [Abstract][Full Text] [Related]
7. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
Luchins DJ
Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts.
Martin BC; Miller LS; Kotzan JA
Schizophr Res; 2001 Mar; 47(2-3):281-92. PubMed ID: 11278146
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of atypical antipsychotic medications versus conventional medication.
Hanrahan P; Luchins DJ; Fabian R; Tolley G
Expert Opin Pharmacother; 2006 Sep; 7(13):1749-58. PubMed ID: 16925502
[TBL] [Abstract][Full Text] [Related]
10. Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.
He X; Wu J; Jiang Y; Liu L; Ye W; Xue H; Montgomery W
BMC Health Serv Res; 2015 Apr; 15():149. PubMed ID: 25880803
[TBL] [Abstract][Full Text] [Related]
11. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
13. Dental Health and the Type of Antipsychotic Treatment in Inpatients with Schizophrenia.
Grinshpoon A; Zusman SP; Weizman A; Ponizovsky AM
Isr J Psychiatry Relat Sci; 2015; 52(2):114-8. PubMed ID: 26431415
[TBL] [Abstract][Full Text] [Related]
14. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
15. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
16. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
[TBL] [Abstract][Full Text] [Related]
17. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
18. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
[TBL] [Abstract][Full Text] [Related]
19. Increasing earnings of social security disability income beneficiaries with serious mental disorder.
Salkever DS; Gibbons B; Drake RE; Frey WD; Hale TW; Karakus M
J Ment Health Policy Econ; 2014 Jun; 17(2):75-90. PubMed ID: 25163103
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
